Breast Cancer Chip
At present, the exact causes of breast cancers are unknown. Identifying the precise causes is critical to developing new ways of preventing the disease. Scientific evidence indicates that a complex mixture of genetic, lifestyle and environmental factors causes breast cancer. Some genetic factors are inherited but most risk factors accumulate over a lifetime due to lifestyle and environmental conditions.
What is known is that breast cancer develops as a result of hundreds of abnormal changes at the cellular level of breast tissue genes. Each patient’s set of gene alterations causes a unique form of breast cancer that should, therefore, be treated specifically for that patient. By analyzing the unique genomic information contained within the cells of diseased tissue, Iris's patented technology platform provides physicians with the advantage of knowing, in advance, how their patients will most likely respond to each of the available clinical treatment options.
The Testing Process
Our molecular test consists of two parts: The first is a precision testing chip that captures the specific tissue biopsy gene profile of a breast cancer patient in as little as 20 minutes. The second is a reference database and computer program that analyzes the specimen gene profile and delivers a rapid, secure, confidential and detailed diagnostic report to the patient’s designated physician.
- The treating physician provides a breast biopsy sample that is processed to recover tissue RNA.
- This sample is then selectively compared to more than a 100 predefined gene markers. In the future, our technology can easily accommodate thousands of gene markers as new scientific discoveries become available.
- The number of target gene markers on the testing chip, to which the tissue RNA binds, creates an optical pattern that is analyzed by the Iris proprietary software. This pattern is then compared to historical clinical reference information contained within our database.
Up to Date Decision Making:
When stored properly, tissue biopsy genetic material does not degrade allowing the Iris technology to generate and share future and more precise gene expression profiles of archived tissue as new research and clinical outcomes are validated. These archived profiles, complete with detailed medical records, demographics and lifestyle information, form a reference database for future comparative analysis. When a current patient's gene profile matches an archived profile, Iris's computer software then searches for the current treatment strategy that is most likely to be successful. With this gene-based information, a physician can, therefore, prescribe a treatment regimen that will have the greatest probability of success while avoiding unnecessary or ill-directed therapy with its accompanying side effects and added expense.
By better understanding the complex causes and the natural history of breast cancer we hope, in the future, to be able to identify effective methods to reduce breast cancer risk and ultimately to be able to prevent the disease and to improve the quality of life for any patient undergoing breast cancer therapy.